Instead, we analyzed the genetic profiles of resected metastatic tumors of another cohort of mCRC in the cBioportal database and found that mutations in APC or TP53 frequently co-occurred with mutations in KRAS. Consistent with that finding, we detected concurrent mutations in APC or TP53 with low-frequency KRAS mutation in the ctDNA of four of our six mCRC patients. This evidence concerns the gene KRAS and metastatic neoplasm.